Peptides and use thereof

• US 9,403,874 B2
• Filed: 07/03/2013
• Issued: 08/02/2016
• Est. Priority Date: 07/03/2012
• Status: Active Grant

• Current Assignee: Il-Yang Pharm. Co., Ltd., Industry-Academic Cooperation Foundation, Sookmyung Women'S University, Samsung Life Insurance Company Limited (Samsung Group)
• Original Assignee: Il-Yang Pharm. Co., Ltd., Industry-Academic Cooperation Foundation, Sookmyung Women'S University, Samsung Life Insurance Company Limited (Samsung Group)
• Inventors: Cho, Dae Ho, Jung, Min Kyung, Ha, Soo Gyeong, Park, Jeong Min, Lee, Jin Young, Kim, Sang Yoon, Park, Seung Beom, Kim, Hee Jong, Ju, Hyun Soo, Lee, Si Nae, Lim, Hae Kyoung, Bang, Sa Ik
• Primary Examiner(s): Steele, Amber D
• Application Number:
  US14/412,020
• Publication Number:
  US 20150175662A1
• Time in Patent Office: 1,126 Days
• US Class Current: 1/1
• CPC Class Codes: A23L 33/18 Peptides; Protein hydrolysates
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/04 for throat disorders
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 7/10 : Antioedematous agents; Diuretics
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 5/06086 : with the first amino acid being basic
• CPC Class Codes: C07K 5/06095 : Arg-amino acid
• CPC Class Codes: C07K 5/06113 : Asp- or Asn-amino acid
• CPC Class Codes: C07K 5/081 : the side chain containing O or S as heteroatoms, e.g. Cys, Ser
• CPC Class Codes: C07K 5/0812 : and aromatic or cycloaliphatic
• CPC Class Codes: C07K 5/0815 : with the first amino acid being basic
• CPC Class Codes: C07K 5/0817 : the first amino acid being Arg
• CPC Class Codes: C07K 5/1019 : with the first amino acid being basic
• CPC Class Codes: C07K 7/06 : having 5 to 11 amino acids
• CPC Class Codes: C07K 7/08 : having 12 to 20 amino acids gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68

Abstract

The present invention relates to novel peptides and use thereof and more specifically is directed to a peptide with anti-inflammatory effect, a polynucleotide encoding the peptide, a pharmaceutical composition comprising the peptide or polynucleotide for preventing or treating inflammatory diseases, an anti-inflammatory drug, an over-the-counter (OTC) drug composition comprising the peptide for preventing or ameliorating inflammation, a health food composition for alleviating or ameliorating inflammation, a cosmetic composition for preventing or ameliorating inflammation, a method for treating inflammatory diseases, comprising administrating the pharmaceutical composition to the subject suspected of having inflammatory disease, a method for preparing a mimetic of the peptide and a method for designing the same.

Claims

1. An isolated peptide represented by an amino acid sequence of SEQ ID NO:

1 or a fragment thereof.

2. The isolated peptide or fragment thereof according to claim 1, wherein the fragment comprises:

a. 6 to 13 consecutive amino acid residues, comprising the 4^th to 6^th amino acids (proline-serine-proline, PSP) of an amino acid sequence of SEQ ID NO;

1;

b. 4 to 10 consecutive amino acid residues, comprising the 10^th to 13^th amino acids (arginine-threonine-aspartic acid-glycine, RTDG) of an amino acid sequence of SEQ ID NO;

1;

c. 6 to 10 consecutive amino acid residues, comprising the 14^th to 16^th amino acids (arginine-threonine-aspartic acid, RTD) of an amino acid sequence of SEQ ID NO;

1;

d. 2 to 6 consecutive amino acid residues, comprising the 12^th and 13^th amino acids (aspartic acid-glycine, DG) of an amino acid sequence of SEQ ID NO;

1;

or

e. 2 to 6 consecutive amino acid residues, comprising the 7^th and 8^th amino acids (arginine-aspartic acid, RD) of an amino acid sequence of SEQ ID NO;

1.

3. The isolated peptide or fragment thereof according to claim 2, wherein the fragment is any one of the amino acid sequences selected from the group consisting of SEQ ID NOs:

2 to 18.

4. The isolated peptide or fragment thereof according to claim 1, wherein the peptide or fragment thereof has an anti-inflammatory effect.

5. A polynucleotide encoding the peptide or fragment thereof of claim 1.

6. A pharmaceutical composition for preventing or treating inflammatory disease, comprising the peptide or fragment thereof of claim 1.

7. The composition according to claim 6, which further comprises a pharmaceutically acceptable carrier.

8. The composition according to claim 6, wherein the inflammatory disease is selected from the group consisting of atopy, psoriasis, dermatitis, allergy, arthritis, rhinitis, otitis media, pharyngolaryngitis, tonsillitis, cystitis, nephritis, pelvic inflammatory disease, Crohn'"'"'s disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematodes (SLE), atherosclerosis, asthma, arteriosclerosis, edema, rheumatoid arthritis, delayed allergy (IV-type allergy), graft rejection, graft-versus-host disease, autoimmune encephalomyelitis, multiple sclerosis, inflammatory bowel disease, cystic fibrosis, diabetic retinopathy, ischemia-reperfusion injury, restenosis, glomerulonephritis and gastrointestinal allergy.

9. An anti-inflammatory drug, comprising the peptide or fragment thereof of claim 1.

10. An over-the-counter (OTC) drug composition for preventing or ameliorating inflammation, comprising the peptide or fragment thereof of claim 1.

11. A health food composition for alleviating or ameliorating inflammation, comprising the peptide or fragment thereof of claim 1.

12. A cosmetic composition for preventing or alleviating inflammation, comprising the peptide or fragment thereof of claim 1.

13. A method for treating inflammatory disease, comprising administrating the composition of claim 6 to a subject suspected of having inflammatory disease.

14. A method for preparing a mimetic of the peptide of claim 1, comprising designing a mimetic of peptide with an anti-inflammatory activity based on the peptide or fragment thereof of claim 1;

and

a. synthesizing the designed mimetic of peptide.

15. A method for designing a mimetic of the peptide with an anti-inflammatory activity from the peptide or fragment thereof of claim 1.